Detalles de la búsqueda
1.
In vitro metabolism of TAK-438, vonoprazan fumarate, a novel potassium-competitive acid blocker.
Xenobiotica
; 47(12): 1027-1034, 2017 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-27414183
2.
Disposition and metabolism of TAK-438 (vonoprazan fumarate), a novel potassium-competitive acid blocker, in rats and dogs.
Xenobiotica
; 47(3): 255-266, 2017 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-27225050
3.
Absorption of TAK-491, a new angiotensin II receptor antagonist, in animals.
Xenobiotica
; 43(2): 182-92, 2013 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-22867273
4.
An unusual metabolic pathway of sipoglitazar, a novel antidiabetic agent: cytochrome P450-catalyzed oxidation of sipoglitazar acyl glucuronide.
Drug Metab Dispos
; 40(2): 249-58, 2012 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-22028317
5.
UDP-glucuronosyltransferase 2B15 (UGT2B15) is the major enzyme responsible for sipoglitazar glucuronidation in humans: retrospective identification of the UGT isoform by in vitro analysis and the effect of UGT2B15*2 mutation.
Drug Metab Pharmacokinet
; 28(6): 475-84, 2013.
Artículo
en Inglés
| MEDLINE | ID: mdl-23648677
6.
Metabolic fate of sipoglitazar, a novel oral PPAR agonist with activities for PPAR-γ, -α and -δ, in rats and monkeys and comparison with humans in vitro.
Drug Metab Pharmacokinet
; 27(2): 223-31, 2012.
Artículo
en Inglés
| MEDLINE | ID: mdl-22123126
7.
Antihypertensive, insulin-sensitising and renoprotective effects of a novel, potent and long-acting angiotensin II type 1 receptor blocker, azilsartan medoxomil, in rat and dog models.
Eur J Pharmacol
; 669(1-3): 84-93, 2011 Nov 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-21816148
Resultados
1 -
7
de 7
1
Próxima >
>>